Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995) Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclosporins
  • Genes, MDR
  • Myelodysplastic Syndromes

abstract

  • CR rates and overall survival were not improved by using PSC-MEC compared to MEC chemotherapy alone in patients with poor-risk AML or high-risk MDS.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5457168

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.07.048

PubMed ID

  • 15020609

Additional Document Info

start page

  • 1078

end page

  • 86

volume

  • 22

number

  • 6